Latitude Pharmaceuticals, Xeris, Juvenile Diabetes Research Foundation International (JDRF) deal

JDRF partnered with Xeris and Latitude to develop formulations of soluble glucagon for use in infusion pumps. Under its deal with Xeris, the biotech will develop G-Pump Glucagon, a stable, room-temperature and non-aqueous injectable glucagon, to treat hypoglycemia. Xeris will receive two years of milestone-based funding, with clinical testing slated to begin in 1Q14 at the Oregon Health & Science University. ...